2022
Antagonism of miR-148a attenuates atherosclerosis progression in APOB TG Apobec -/- Ldlr +/- mice: A brief report
Rotllan N, Zhang X, Canfrán-Duque A, Goedeke L, Griñán R, Ramírez CM, Suárez Y, Fernández-Hernando C. Antagonism of miR-148a attenuates atherosclerosis progression in APOB TG Apobec -/- Ldlr +/- mice: A brief report. Biomedicine & Pharmacotherapy 2022, 153: 113419. PMID: 36076541, PMCID: PMC11140622, DOI: 10.1016/j.biopha.2022.113419.Peer-Reviewed Original ResearchConceptsProgression of atherosclerosisMiR-148aLipoprotein cholesterolAtherosclerotic lesionsHigh-density lipoprotein cholesterolLow-density lipoprotein cholesterolAnti-inflammatory effectsAnti-inflammatory genesMacrophage cholesterol effluxWestern-style dietMiR-148a levelsHepatic gene expressionMurine primary macrophagesAntiatherogenic effectsAtherosclerosis progressionInflammatory responseTherapeutic silencingLipoprotein metabolismPlaque stabilityCholesterol effluxPrimary macrophagesPlaque sizeCholesterol homeostasisLesionsMRNA levels
2001
Dose-dependent effects of lovastatin on cell cycle progression. Distinct requirement of cholesterol and non-sterol mevalonate derivatives
Martı́nez-Botas J, Ferruelo A, Suárez Y, Fernández C, Gómez-Coronado D, Lasunción M. Dose-dependent effects of lovastatin on cell cycle progression. Distinct requirement of cholesterol and non-sterol mevalonate derivatives. Biochimica Et Biophysica Acta 2001, 1532: 185-194. PMID: 11470239, DOI: 10.1016/s1388-1981(01)00125-1.Peer-Reviewed Original ResearchConceptsCell proliferationLow-density lipoprotein cholesterolCell cycle progressionDose-dependent effectCell cycle distributionCell cycleCycle progressionLipoprotein cholesterolConcentrations of lovastatinCholesterol supplyCycle distributionCholesterolLovastatinHuman cell linesCell linesCholesterol biosynthesisCholesterol-free mediumNormal cell cyclingM phaseProgressionProliferationPresent studyHL-60Mevalonate derivativesCell cycling